FI972654A0 - Meletsitoosia laimentimena sisältävät jauhekoostumukset - Google Patents

Meletsitoosia laimentimena sisältävät jauhekoostumukset

Info

Publication number
FI972654A0
FI972654A0 FI972654A FI972654A FI972654A0 FI 972654 A0 FI972654 A0 FI 972654A0 FI 972654 A FI972654 A FI 972654A FI 972654 A FI972654 A FI 972654A FI 972654 A0 FI972654 A0 FI 972654A0
Authority
FI
Finland
Prior art keywords
melezitios
diluent
formulations containing
powder formulations
powder
Prior art date
Application number
FI972654A
Other languages
English (en)
Swedish (sv)
Other versions
FI972654A (fi
Inventor
Kjell Baeckstroem
Ann Johansson
Helena Linden
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of FI972654A0 publication Critical patent/FI972654A0/fi
Publication of FI972654A publication Critical patent/FI972654A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
FI972654A 1994-12-22 1997-06-19 Meletsitoosia laimentimena sisältävät jauhekoostumukset FI972654A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9404468A SE9404468D0 (sv) 1994-12-22 1994-12-22 Powder formulations
PCT/SE1995/001541 WO1996019207A1 (en) 1994-12-22 1995-12-19 Powder formulations containing melezitose as a diluent

Publications (2)

Publication Number Publication Date
FI972654A0 true FI972654A0 (fi) 1997-06-19
FI972654A FI972654A (fi) 1997-06-19

Family

ID=20396435

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972654A FI972654A (fi) 1994-12-22 1997-06-19 Meletsitoosia laimentimena sisältävät jauhekoostumukset

Country Status (34)

Country Link
US (1) US6004574A (fi)
EP (2) EP0799030B1 (fi)
JP (1) JPH10510828A (fi)
KR (1) KR100391873B1 (fi)
CN (1) CN1080114C (fi)
AR (1) AR002261A1 (fi)
AT (2) ATE220900T1 (fi)
AU (1) AU702898B2 (fi)
BR (1) BR9510422A (fi)
CA (1) CA2206803A1 (fi)
CZ (1) CZ288487B6 (fi)
DE (2) DE69533294T2 (fi)
DK (2) DK1224929T3 (fi)
EE (1) EE03381B1 (fi)
ES (2) ES2222306T3 (fi)
FI (1) FI972654A (fi)
HK (1) HK1003619A1 (fi)
HU (1) HU217975B (fi)
IL (1) IL116459A (fi)
IS (1) IS1848B (fi)
MY (1) MY114211A (fi)
NO (1) NO315966B1 (fi)
NZ (1) NZ298168A (fi)
PL (1) PL183944B1 (fi)
PT (2) PT1224929E (fi)
RU (1) RU2144819C1 (fi)
SA (1) SA95160484B1 (fi)
SE (1) SE9404468D0 (fi)
SK (1) SK283147B6 (fi)
TR (1) TR199501632A1 (fi)
TW (1) TW474823B (fi)
UA (1) UA44757C2 (fi)
WO (1) WO1996019207A1 (fi)
ZA (1) ZA9510753B (fi)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632456B1 (en) * 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
ATE236617T1 (de) * 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
JP2001518916A (ja) * 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ 結晶インスリンを含有する肺投与のための治療用粉末調合物
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
WO2000061178A1 (en) * 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
EP1169053A1 (en) 1999-04-13 2002-01-09 Inhale Therapeutic Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
GB0011807D0 (en) * 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
CN1446077A (zh) * 2000-08-07 2003-10-01 耐科塔医药公司 具有最小聚集的可吸入喷雾干燥4－螺旋束蛋白粉剂
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
KR20040073438A (ko) 2001-11-19 2004-08-19 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
RU2393168C2 (ru) 2004-07-19 2010-06-27 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
JP5613657B2 (ja) 2008-03-28 2014-10-29 ヘイル バイオファーマ ベンチャーズ，エルエルシー ベンゾジアゼピン組成物の投与
CN101618023B (zh) * 2008-06-30 2011-11-30 江苏先声药物研究有限公司 一种制备微粉化蛋白的方法
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
KR101872203B1 (ko) 2010-04-20 2018-08-02 옥타파마 아게 약학 단백질을 위한 신규한 안정화제
EP4085899A1 (en) 2011-06-14 2022-11-09 Neurelis, Inc. Administration of benzodiazepine
US9480966B2 (en) * 2012-04-30 2016-11-01 General Electric Company Substrates and methods for collection, stabilization and elution of biomolecules
JP6533777B2 (ja) * 2014-03-25 2019-06-19 国立大学法人 香川大学 希少糖を有効成分とするマラリア伝播阻止剤およびマラリア原虫の発育阻害剤
EP3160261B1 (en) * 2014-06-30 2018-06-20 Tate & Lyle Ingredients Americas LLC Coating compositions for consumable articles
ES2841933T3 (es) 2014-10-31 2021-07-12 Univ Monash Formulación en polvo
ES2912965T3 (es) 2015-09-09 2022-05-30 Drawbridge Health Inc Dispositivos para la recopilación, estabilización y conservación de muestras
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (fi) * 1957-01-31 1957-04-11
GB1144905A (en) * 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
SE7812207L (sv) * 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
DE3326089A1 (de) * 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
EP0223831B1 (en) * 1985-05-22 1992-07-15 Liposome Technology, Inc. Liposome inhalation method and system
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
EP0360340A1 (en) * 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5176132A (en) * 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
DE69306755T2 (de) * 1992-01-21 1997-04-10 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
CZ286632B6 (cs) * 1992-09-29 2000-05-17 Inhale Therapeutic Systems Farmaceutický prostředek
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation

Also Published As

Publication number Publication date
TR199501632A1 (tr) 1997-03-21
DK0799030T3 (da) 2002-09-16
SE9404468D0 (sv) 1994-12-22
PL183944B1 (pl) 2002-08-30
DK1224929T3 (da) 2004-10-04
IL116459A (en) 2002-11-10
EP0799030A1 (en) 1997-10-08
NZ298168A (en) 1999-08-30
ZA9510753B (en) 1996-06-24
EP0799030B1 (en) 2002-07-24
NO315966B1 (no) 2003-11-24
ES2177674T3 (es) 2002-12-16
ES2222306T3 (es) 2005-02-01
IS1848B (is) 2003-02-07
CN1171049A (zh) 1998-01-21
EP1224929A2 (en) 2002-07-24
CZ194697A3 (en) 1997-10-15
SA95160484B1 (ar) 2005-10-01
CN1080114C (zh) 2002-03-06
US6004574A (en) 1999-12-21
IL116459A0 (en) 1996-03-31
BR9510422A (pt) 1998-07-07
UA44757C2 (uk) 2002-03-15
DE69527542T2 (de) 2003-01-30
EP1224929A3 (en) 2002-12-18
NO972660D0 (no) 1997-06-10
ATE220900T1 (de) 2002-08-15
PT799030E (pt) 2002-11-29
CA2206803A1 (en) 1996-06-27
HUT77648A (hu) 1998-07-28
AU702898B2 (en) 1999-03-11
SK81297A3 (en) 1997-11-05
EE03381B1 (et) 2001-04-16
DE69533294D1 (de) 2004-08-26
WO1996019207A1 (en) 1996-06-27
ATE271382T1 (de) 2004-08-15
TW474823B (en) 2002-02-01
FI972654A (fi) 1997-06-19
DE69533294T2 (de) 2005-05-19
KR100391873B1 (ko) 2003-10-17
EE9700135A (et) 1997-12-15
HU217975B (hu) 2000-05-28
HK1003619A1 (en) 1998-11-06
NO972660L (no) 1997-06-10
IS4495A (is) 1997-06-03
AU4359296A (en) 1996-07-10
DE69527542D1 (de) 2002-08-29
JPH10510828A (ja) 1998-10-20
AR002261A1 (es) 1998-03-11
EP1224929B1 (en) 2004-07-21
SK283147B6 (sk) 2003-03-04
MY114211A (en) 2002-08-30
CZ288487B6 (en) 2001-06-13
MX9704551A (es) 1997-10-31
PT1224929E (pt) 2004-10-29
PL320751A1 (en) 1997-10-27
RU2144819C1 (ru) 2000-01-27

Similar Documents

Publication Publication Date Title
FI972654A (fi) Meletsitoosia laimentimena sisältävät jauhekoostumukset
FI946064A (fi) Apuaineita sisältävä rokotekoostumus
DE69419519T2 (de) Riechstoffe formulierungen
DE69836106D1 (de) Stanolester enthaltende Zusammensetzungen
NO983581L (no) Lysfiltrerende kosmetisk sammensetning
DE69423670T2 (de) Siloxy-aluminoxan-Zusammensetzungen
FI955048A (fi) Kosmeettisia koostumuksia
DK0799297T3 (da) Fortykkede persyresammensætninger
PT946100E (pt) Composicoes herbicidas contendo n-¬(4,6-dimetoxipirimidin-2-il)aminocarbonil|-5-metilsulfonamidometil-2-alcoxicarbonilbenzenossulfonamidas
CY2005007I1 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
DK0799298T3 (da) Fortykkede persyresammensætninger
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
ATE357237T1 (de) Formulierungen enthaltend cefuroxim-axetil
FI941447A (fi) Suun kautta annettavat, kapseleina olevat ubidekarenonivalmisteet
BR9407124A (pt) Composições contendo surfactante
NO985564D0 (no) Lysfiltrerende sammensetning
NO20012727L (no) 3,4,5-trisubstituerte arylnitronforbindelser og farmasöytiske sammensetninger som inneholder samme
ITMI951395A0 (it) Formulazioni di f-silicone
KR970702904A (ko) 중합성 조성물(polymerizable compositions)
IL134651A0 (en) Pharmaceutical compositions containing an anti-androgen
FI963631A0 (fi) Insektisidisia tehoainekoostumuksia
EP0793491A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING LYCOPENE
MA23731A1 (fr) Compositions detegentes
AU8744998A (en) Stabled thickened bleaching compositions
BR9607226A (pt) Composições herbicidas mistas